ArticleCell & bioscience2025
A CCL5
Article in Cell & bioscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundIn rheumatoid arthritis (RA), fibroblast-like synoviocytes (FLS) acquire an aggressive phenotype promoting inflammation and joint damage. While FLS interactions with recruited T cells are established, drivers of FLS aggressiveness and the role of CD20+CD8+ T cells remain undefined. This study explores CD20+CD8+ T cells in RA, focusing on inducing pathogenic FLS transformation.
methodsSingle-cell RNA sequencing (scRNA-seq) was employed to delineate the transcriptomic profile of CD20+CD8+ T cells. Flow cytometric analysis was used to quantify the frequency of CCL5+CD20+CD8+ T cells. To investigate cellular crosstalk, FLS were cultured with conditioned medium from CD20+CD8+ T cells (CD20+CD8+ T-CM). Phenotypic transformation of FLS was assessed through flow cytometry and transwell migration assays, and bulk RNA sequencing characterized the molecular signatures associated with the aggressive FLS phenotype. Signaling pathways associated with FLS activation induced by CD20+CD8+ T-CM were examined using western blotting. In vivo functional validation using the collagen-induced arthritis (CIA) model included assessments of clinical scores, histopathology, radiographic bone integrity, and synovial immunofluorescence after adoptive transfer of CD20+CD8+ T cells.
resultsscRNA-seq identified a CCL5-high subset within CD20+CD8+ T cells, and flow cytometry revealed elevated CCL5+CD20+CD8+ T cells in RA patients. This subset positively correlated with disease activity and exhibited heightened chemotactic and migratory capacity. Culturing FLS with CD20+CD8+ T-CM induced transformation of FLS toward an invasive FAPα+ phenotype, accompanied by enhanced migratory capacity and elevated CCL5 production in culture supernatants. Notably, CCR1 or CCR5 antagonists reduced the frequency of FAPα+ FLS. Mechanistically, bioinformatics analysis identified JAK-STAT activation in FLS transcriptomes cultured with CD20+CD8+ T-CM. In vitro experiments confirmed that pathway blockade inhibited the induction of invasive FAPα+ FLS phenotype. Adoptive transfer of CD20+CD8+ T cells exacerbated joint damage and accelerated disease progression in CIA models by promoting synovial infiltration and inducing pathogenic FAPα+ FLS.
conclusionsOur findings suggest CCL5+CD20+CD8+ T cells as key pathogenic drivers in RA, promoting aggressive FAPα+ FLS transformation via CCL5-mediated JAK-STAT signaling, revealing a novel immunopathogenesis of RA and identifying CCL5+CD20+CD8+ T cells as potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.